“Laurus Labs – Building Momentum Through Innovation, APIs and Global Pharma Partnerships.”

Technical Analysis (Daily Chart Perspective) Based on the daily chart structure,

Laurus Labs has recently shown signs of recovery after a corrective phase. The stock previously declined sharply from higher levels and eventually formed a strong base around the ₹920–₹940 zone. From this support area the price structure started developing higher lows, indicating the possibility of a gradual trend reversal. Over the last few sessions the stock has attempted to move above short-term moving averages which suggests improving momentum and increasing buying interest from market participants. Business Segments and Growth Drivers The company operates through multiple business segments including Generic APIs, Finished Dosage Formulations, Contract Development and Manufacturing (CDMO), and Biotechnology. Laurus Labs has also expanded its capabilities in advanced therapies and fermentation technologies which may drive long-term growth. Its integrated model allows the company to serve global pharmaceutical clients across multiple stages of the drug development and manufacturing process. Important Facts About Laurus Labs Laurus Labs was founded by pharmaceutical entrepreneur Dr. Satyanarayana Chava and has grown into a globally recognized pharmaceutical manufacturer. The company has a strong presence in the antiretroviral drug segment which is used in the treatment of HIV. It also has a large number of ongoing research and development projects across different therapeutic areas. Laurus Labs continues to invest heavily in innovation and manufacturing expansion to strengthen its long-term growth strategy.